ABTL-0812 - CAS 57818-44-7
Catalog number: 57818-44-7
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
C18H31O3
Molecular Weight:
294.93
COA:
Inquire
Targets:
mTOR
Description:
ABTL-0812 is an orally bioavailable, lipid analogue and inhibitor of raptor-mammalian target of rapamycin (mTOR), rictor-mTOR and dihydrofolate reductase with potential antineoplastic activity. It binds to and inhibits both mTORC1 and mTORC2, which may result in apoptosis and a decrease in proliferation in mTORC1/2-expressing tumor cells upon oral administration. It was developed by Ability Pharmaceuticals and is in phase I/II clinical trials for the treatment of solid tumors. It received orphan drug designation in the E.U. and in the U.S. for the treatment of neuroblastoma in 2015.
Publictions citing BOC Sciences Products
  • >> More
Purity:
98%
Appearance:
Solid powder
Synonyms:
ABTL0812;(9Z,12Z)-2-hydroxyoctadeca-9,12-dienoate
Solubility:
Soluble in DMSO, not in water
Storage:
-20°C Freezer
MSDS:
Inquire
Application:
ABTL-0812 has potential antineoplastic activity. It is used for the treatment of solid tumors
Quality Standard:
In-house standard
Quantity:
Milligrams-Grams
Boiling Point:
409.7±30.0 °C | Condition: Press: 760 Torr
Density:
0.970±0.06 g/cm3 | Condition: Temp: 20 °C Press: 760 Torr
InChIKey:
AFDSETGKYZMEEA-HZJYTTRNSA-N
InChI:
InChI=1/C18H32O3/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17(19)18(20)21/h6-7,9-10,17,19H,2-5,8,11-16H2,1H3,(H,20,21)/b7-6-,10-9-/f/h20H
Canonical SMILES:
CCCCC/C=C\C/C=C\CCCCCCC(O)C([O-])=O
Current Developer:
ABTL-0812 was developed by Ability Pharmaceuticals and is in phase I/II clinical trials. It received orphan drug designation in the E.U. and in the U.S. for the treatment of neuroblastoma in 2015.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related mTOR Products


CAS 1028385-32-1 BEZ235 Tosylate

BEZ235 Tosylate
(CAS: 1028385-32-1)

BEZ235 tosylate is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assay...

CAS 1394076-92-6 GNE-317

GNE-317
(CAS: 1394076-92-6)

GNE-317 is a potent and selective PI3K inhibitor with potential anticncer activity. GNE-317 targets the PI3K pathway and can cross the Blood–Brain Barrier. GNE-...

CAS 1062169-56-5 WYE-354

WYE-354
(CAS: 1062169-56-5)

WYE-354 is a potent cell-permeable inhibitor of mTOR (IC50 = 4.3 nM) which blocks signaling through both mTOR complex 1 (mTORC1) and mTORC2.

CAS 162635-04-3 Temsirolimus

Temsirolimus
(CAS: 162635-04-3)

Temsirolimus potently inhibits mTOR kinase activity with IC50 of 1.76 μM, similar to that of rapamycin with IC50 of 1.74 μM.

CAS 1009298-09-2 AZD-8055

AZD-8055
(CAS: 1009298-09-2)

AZD-8055 is an inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity. mTOR kinase inhibitor AZD8055 inhibits the serine/t...

AZD-3147
(CAS: 1101810-02-9)

AZD-3147 is an extremely potent and selective dual inhibitor of mTORC1 and mTORC2. It exhibits >300-fold selectivity for mTOR over PI 3-kinase isoforms. It has ...

CAS 936890-98-1 OSI-027

OSI-027
(CAS: 936890-98-1)

mTOR kinase inhibitor OSI-027 is an orally bioavailable mammalian target of rapamycin (mTOR) kinase inhibitor with potential antineoplastic activity. mTOR kinas...

CAS 1429639-50-8 CZ415

CZ415
(CAS: 1429639-50-8)

CZ415 is a highly selective potent mTOR inhibitor with little activity on other lipid and protein kinases with efficacy in a collagen induced arthritis model an...

CAS 915019-65-7 Dactolisib

Dactolisib
(CAS: 915019-65-7)

Dactolisib, also known as BEZ235, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. BEZ235 speci...

CAS 1224844-38-5 MLN0128

MLN0128
(CAS: 1224844-38-5)

MLN0128, also known as INK128, is a TORC1/2 inhibitor, is also an orally bioavailable inhibitor of raptor-mTOR (TOR complex 1 or TORC1) and rictor-mTOR (TOR co...

CAS 934529-30-3 XL PI3K/mTOR inhibitor

XL PI3K/mTOR inhibitor
(CAS: 934529-30-3)

An orally bioactive PI3K/mTOR tyrosine kinase inhibitor.

CC-115 hydrochloride
(CAS: 1300118-55-1)

The hydrochloride salt form of CC-115 which is a mTOR / DNA-PK inhibitor that probably has antineoplastic effect through influencing the cellular proliferation ...

CC-115
(CAS: 1228013-15-7)

CC-115, a DNA-PK and mTOR inhibitor, has been found to have probable anticarcinoma effect. IC50:13 nM and 21 nM for DNA-PK and mTOR respectively.

CAS 1086062-66-9 Omipalisib

Omipalisib
(CAS: 1086062-66-9)

Omipalisib, also known as GSK2126458, is asmall-molecule pyridylsulfonamide inhibitor of phosphatidylinositol 3-kinase (PI3K) with potential antineoplastic acti...

DMH-25
(CAS: 1685280-21-0)

DMH-25, a chromene derivative, could be a covalent mTOR inhibitor that has be found to exhibit activity in restraining the growth and metastasis of triple-negat...

CAS 53123-88-9 Rapamycin

Rapamycin
(CAS: 53123-88-9)

Rapamycin is a mTOR inhibitor immunosuppressant and kinase inhibitor with both antifungal and antineoplastic properties. It selectively inhibits the transcripti...

GDC-0084
(CAS: 1382979-44-3)

GDC-0084, a PI3K inhibitor, has been found to have probable antineoplastic effect and could pass blood-brain barrier with favourable penetration. It was just li...

CAS 938440-64-3 KU-0063794

KU-0063794
(CAS: 938440-64-3)

Ku-0063794 inhibits both mTORC1 and mTORC2 with an IC50 of approximately 10 nM, but does not suppress the activity of 76 other protein kinases or seven lipid ki...

PQR530
(CAS: 1927857-61-1)

PQR530 is a potent dual pan PI3K/mTOR inhibitor undergoing phase II clinical trials in 2016. Aberrant activation of the PI3K/mTOR signaling pathway promotes the...

CAS 1197160-78-3 Gedatolisib (PF-05212384, PKI-587)

Gedatolisib (PF-05212384, PKI-587)
(CAS: 1197160-78-3)

Gedatolisib (PF-05212384, PKI-587) is a highly potent dual inhibitor of PI3Kα, PI3Kγ and mTOR with IC50 of 0.4 nM, 5.4 nM and 1.6 nM, respectively. Phase 2.

Quick Inquiry

Verification code

Featured Items